https://lmct.research.vub.be/

Medicine & Life Sciences

1. Dendritic Cells 100%
2. Melanoma 89%
3. Single-Domain Antibodies 75%
4. T-Lymphocytes 64%
5. Neoplasms 62%
6. Immunotherapy 58%
7. Myeloid-Derived Suppressor Cells 41%
8. Messenger RNA 41%
9. trimix 38%
10. Ipilimumab 37%
11. Multiple Myeloma 33%
12. Therapeutics 28%
13. pembrolizumab 25%
14. Antigens 24%
15. Nivolumab 23%
16. Neoplasm Antigens 23%
17. Vaccination 21%
18. Vaccines 21%
19. Glioblastoma 19%
20. Myeloid Cells 18%
21. Antigen-Presenting Cells 17%
22. Tumor Microenvironment 17%
23. Survival 17%
24. Axitinib 16%
25. avelumab 16%
26. Electroporation 16%
27. Macrophages 15%
28. Clinical Trials, Phase I 13%
29. Safety 12%
30. Immunity 12%
31. In Vitro Techniques 12%
32. Ligands 12%
33. dabrafenib 12%
34. Colorectal Neoplasms 12%
35. Bone Marrow 11%
36. Neoplasm Metastasis 11%
37. Radioisotopes 11%
38. Cytotoxic T-Lymphocytes 11%
39. Liver 11%
40. Phase II Clinical Trials 10%
41. Immunogenic Cell Death 10%
42. Genes 10%
43. Tumor Burden 10%
44. Monocytes 10%
45. Bispecific Antibodies 9%
46. trametinib 9%
47. Pharmaceutical Preparations 9%
48. Cytokines 9%
49. HIV 9%
50. Belgium 9%
51. HIV-1 8%
52. CD40 Ligand 8%
53. Epitopes 8%
54. talimogene laherparepvec 8%
55. Immunosuppressive Agents 8%
56. Glioma 8%
57. mannose receptor 8%
58. Proteins 7%
59. Immune System 7%
60. Circulating Tumor DNA 7%
61. Granzymes 7%
62. Injections 7%
63. Stem Cell Transplantation 7%
64. Growth 7%
65. Regulatory T-Lymphocytes 7%
66. Tumor-Infiltrating Lymphocytes 7%
67. Cell- and Tissue-Based Therapy 7%
68. Progression-Free Survival 7%
69. Clinical Trials 7%
70. Mutation 7%
71. Hepatic Stellate Cells 7%
72. Microsatellite Instability 7%
73. STAT3 Transcription Factor 7%
74. Fibrosis 7%
75. DNA Mismatch Repair 7%
76. Peptides 6%
77. Skin 6%
78. Recurrence 6%
79. Lenalidomide 6%
80. Antibodies 6%
81. Fluorodeoxyglucose F18 6%
82. Antigen Presentation 6%
83. Apoptosis 6%
84. Lung 6%
85. Epigenomics 6%
86. Biomarkers 6%
87. Cell Line 6%
88. Breast Neoplasms 6%
89. Immunoglobulin Fragments 6%
90. Temozolomide 5%
91. Actinium-225 5%
92. Ovalbumin 5%
93. Bortezomib 5%
94. RNA 5%
95. Neuropilin-1 5%
96. Disease Progression 5%
97. Cell Death 5%
98. CD8 Antigens 5%
99. Immunologic Monitoring 5%
100. Lymphoma 5%